357 related articles for article (PubMed ID: 16860909)
1. Economic evaluation of varicella vaccination in Spain: results from a dynamic model.
Lenne X; Diez Domingo J; Gil A; Ridao M; Lluch JA; Dervaux B
Vaccine; 2006 Nov; 24(47-48):6980-9. PubMed ID: 16860909
[TBL] [Abstract][Full Text] [Related]
2. Can varicella be eliminated by vaccination? Potential clinical and economic effects of universal childhood varicella immunisation in Germany.
Wutzler P; Neiss A; Banz K; Goertz A; Bisanz H
Med Microbiol Immunol; 2002 Oct; 191(2):89-96. PubMed ID: 12410347
[TBL] [Abstract][Full Text] [Related]
3. Varicella vaccination in Italy : an economic evaluation of different scenarios.
Coudeville L; Brunot A; Giaquinto C; Lucioni C; Dervaux B
Pharmacoeconomics; 2004; 22(13):839-55. PubMed ID: 15329030
[TBL] [Abstract][Full Text] [Related]
4. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States.
Ortega-Sanchez IR; Meltzer MI; Shepard C; Zell E; Messonnier ML; Bilukha O; Zhang X; Stephens DS; Messonnier NE;
Clin Infect Dis; 2008 Jan; 46(1):1-13. PubMed ID: 18171206
[TBL] [Abstract][Full Text] [Related]
5. Cost-benefit analysis of universal varicella vaccination in the U.S. taking into account the closely related herpes-zoster epidemiology.
Goldman GS
Vaccine; 2005 May; 23(25):3349-55. PubMed ID: 15837242
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of universal childhood vaccination against varicella in Brazil.
Valentim J; Sartori AM; de Soárez PC; Amaku M; Azevedo RS; Novaes HM
Vaccine; 2008 Nov; 26(49):6281-91. PubMed ID: 18674582
[TBL] [Abstract][Full Text] [Related]
7. An economic analysis of the universal varicella vaccination program in the United States.
Zhou F; Ortega-Sanchez IR; Guris D; Shefer A; Lieu T; Seward JF
J Infect Dis; 2008 Mar; 197 Suppl 2():S156-64. PubMed ID: 18419391
[TBL] [Abstract][Full Text] [Related]
8. The economic value of childhood varicella vaccination in France and Germany.
Coudeville L; Brunot A; Szucs TD; Dervaux B
Value Health; 2005; 8(3):209-22. PubMed ID: 15877593
[TBL] [Abstract][Full Text] [Related]
9. An economic evaluation of varicella vaccination in Italian adolescents.
Thiry N; Beutels P; Tancredi F; Romanò L; Zanetti A; Bonanni P; Gabutti G; Van Damme P
Vaccine; 2004 Sep; 22(27-28):3546-62. PubMed ID: 15315834
[TBL] [Abstract][Full Text] [Related]
10. Varicella epidemiology and cost-effectiveness analysis of universal varicella vaccination program in Taiwan.
Tseng HF; Tan HF; Chang CK
Southeast Asian J Trop Med Public Health; 2005 Nov; 36(6):1450-8. PubMed ID: 16610647
[TBL] [Abstract][Full Text] [Related]
11. [Modelling the impact of vaccination on the epidemiology of varicella zoster virus].
Bonmarin I; Santa-Olalla P; Lévy-Bruhl D
Rev Epidemiol Sante Publique; 2008 Oct; 56(5):323-31. PubMed ID: 18951741
[TBL] [Abstract][Full Text] [Related]
12. Economic evaluation of the 7-vaccine routine childhood immunization schedule in the United States, 2001.
Zhou F; Santoli J; Messonnier ML; Yusuf HR; Shefer A; Chu SY; Rodewald L; Harpaz R
Arch Pediatr Adolesc Med; 2005 Dec; 159(12):1136-44. PubMed ID: 16330737
[TBL] [Abstract][Full Text] [Related]
13. Economic burden of varicella in Singapore--a cost benefit estimate of implementation of a routine varicella vaccination.
Jean-Jasmin LM; Lynette SP; Stefan M; Kai CS; Chew FT; Wah LB
Southeast Asian J Trop Med Public Health; 2004 Sep; 35(3):693-6. PubMed ID: 15689089
[TBL] [Abstract][Full Text] [Related]
14. Economic evaluation of varicella vaccination in Italian children and adolescents according to different intervention strategies: the burden of uncomplicated hospitalised cases.
Bonanni P; Boccalini S; Bechini A; Banz K
Vaccine; 2008 Oct; 26(44):5619-26. PubMed ID: 18723062
[TBL] [Abstract][Full Text] [Related]
15. One dose of varicella vaccine does not prevent school outbreaks: is it time for a second dose?
Lopez AS; Guris D; Zimmerman L; Gladden L; Moore T; Haselow DT; Loparev VN; Schmid DS; Jumaan AO; Snow SL
Pediatrics; 2006 Jun; 117(6):e1070-7. PubMed ID: 16740809
[TBL] [Abstract][Full Text] [Related]
16. [Impact of universal varicella vaccination in Germany: an epidemiological and economic analysis].
Knuf M; Neiss A; Wutzler P
Klin Padiatr; 2006; 218(4):203-12. PubMed ID: 16819701
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of varicella vaccination programs: an update of the literature.
Rozenbaum MH; van Hoek AJ; Vegter S; Postma MJ
Expert Rev Vaccines; 2008 Aug; 7(6):753-82. PubMed ID: 18665775
[TBL] [Abstract][Full Text] [Related]
18. [A full economic evaluation of extensive vaccination against rotavirus with RIX4414 vaccine at National and Regional level in Italy].
Vitale F; Barbieri M; Dirodi B; Vitali Rosati G; Franco E
Ann Ig; 2013; 25(1):43-56. PubMed ID: 23435779
[TBL] [Abstract][Full Text] [Related]
19. Economic evaluation of meningococcal serogroup C conjugate vaccination programmes in The Netherlands and its impact on decision-making.
Welte R; van den Dobbelsteen G; Bos JM; de Melker H; van Alphen L; Spanjaard L; Rümke HC; Postma MJ
Vaccine; 2004 Dec; 23(4):470-9. PubMed ID: 15530695
[TBL] [Abstract][Full Text] [Related]
20. Establishing the health and economic impact of influenza vaccination within the European Union 25 countries.
Ryan J; Zoellner Y; Gradl B; Palache B; Medema J
Vaccine; 2006 Nov; 24(47-48):6812-22. PubMed ID: 17034909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
